Global Recombinant Insulin Analogue Market Research Report 2024

Publication ID:

PB507241662

Publication Date:

July 1, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.
The global Recombinant Insulin Analogue market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Insulin Analogue is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Insulin Analogue is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Insulin Analogue include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Insulin Analogue, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Insulin Analogue.
Report Scope
The Recombinant Insulin Analogue market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Insulin Analogue market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Insulin Analogue manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd
Segment by Type
Quick-Acting
Medium Effect
Long-Lasting
Super Long-Acting
Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Insulin Analogue manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Insulin Analogue in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Recombinant Insulin Analogue Market Overview
1.1 Product Overview and Scope of Recombinant Insulin Analogue
1.2 Recombinant Insulin Analogue Segment by Type
1.2.1 Global Recombinant Insulin Analogue Market Value Comparison by Type (2024-2030)
1.2.2 Quick-Acting
1.2.3 Medium Effect
1.2.4 Long-Lasting
1.2.5 Super Long-Acting
1.3 Recombinant Insulin Analogue Segment by Application
1.3.1 Global Recombinant Insulin Analogue Market Value by Application: (2024-2030)
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Global Recombinant Insulin Analogue Market Size Estimates and Forecasts
1.4.1 Global Recombinant Insulin Analogue Revenue 2019-2030
1.4.2 Global Recombinant Insulin Analogue Sales 2019-2030
1.4.3 Global Recombinant Insulin Analogue Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Insulin Analogue Market Competition by Manufacturers
2.1 Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Insulin Analogue Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Insulin Analogue Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Insulin Analogue Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Insulin Analogue, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Insulin Analogue, Product Type & Application
2.7 Recombinant Insulin Analogue Market Competitive Situation and Trends
2.7.1 Recombinant Insulin Analogue Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Insulin Analogue Players Market Share by Revenue
2.7.3 Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Insulin Analogue Retrospective Market Scenario by Region
3.1 Global Recombinant Insulin Analogue Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Insulin Analogue Global Recombinant Insulin Analogue Sales by Region: 2019-2030
3.2.1 Global Recombinant Insulin Analogue Sales by Region: 2019-2024
3.2.2 Global Recombinant Insulin Analogue Sales by Region: 2025-2030
3.3 Global Recombinant Insulin Analogue Global Recombinant Insulin Analogue Revenue by Region: 2019-2030
3.3.1 Global Recombinant Insulin Analogue Revenue by Region: 2019-2024
3.3.2 Global Recombinant Insulin Analogue Revenue by Region: 2025-2030
3.4 North America Recombinant Insulin Analogue Market Facts & Figures by Country
3.4.1 North America Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Insulin Analogue Sales by Country (2019-2030)
3.4.3 North America Recombinant Insulin Analogue Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Insulin Analogue Market Facts & Figures by Country
3.5.1 Europe Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Insulin Analogue Sales by Country (2019-2030)
3.5.3 Europe Recombinant Insulin Analogue Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Insulin Analogue Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Insulin Analogue Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Insulin Analogue Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Insulin Analogue Market Facts & Figures by Country
3.7.1 Latin America Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Insulin Analogue Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Insulin Analogue Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Insulin Analogue Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Insulin Analogue Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Insulin Analogue Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Insulin Analogue Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Insulin Analogue Sales by Type (2019-2030)
4.1.1 Global Recombinant Insulin Analogue Sales by Type (2019-2024)
4.1.2 Global Recombinant Insulin Analogue Sales by Type (2025-2030)
4.1.3 Global Recombinant Insulin Analogue Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Insulin Analogue Revenue by Type (2019-2030)
4.2.1 Global Recombinant Insulin Analogue Revenue by Type (2019-2024)
4.2.2 Global Recombinant Insulin Analogue Revenue by Type (2025-2030)
4.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Insulin Analogue Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Insulin Analogue Sales by Application (2019-2030)
5.1.1 Global Recombinant Insulin Analogue Sales by Application (2019-2024)
5.1.2 Global Recombinant Insulin Analogue Sales by Application (2025-2030)
5.1.3 Global Recombinant Insulin Analogue Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Insulin Analogue Revenue by Application (2019-2030)
5.2.1 Global Recombinant Insulin Analogue Revenue by Application (2019-2024)
5.2.2 Global Recombinant Insulin Analogue Revenue by Application (2025-2030)
5.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Insulin Analogue Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk A/S
6.1.1 Novo Nordisk A/S Corporation Information
6.1.2 Novo Nordisk A/S Description and Business Overview
6.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Product Portfolio
6.1.5 Novo Nordisk A/S Recent Developments/Updates
6.2 Eli Lilly and Company
6.2.1 Eli Lilly and Company Corporation Information
6.2.2 Eli Lilly and Company Description and Business Overview
6.2.3 Eli Lilly and Company Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly and Company Recombinant Insulin Analogue Product Portfolio
6.2.5 Eli Lilly and Company Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Recombinant Insulin Analogue Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Gan & Lee Pharmaceuticals Co., Ltd
6.4.1 Gan & Lee Pharmaceuticals Co., Ltd Corporation Information
6.4.2 Gan & Lee Pharmaceuticals Co., Ltd Description and Business Overview
6.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Portfolio
6.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates
6.5 The United Laboratories International Holdings Limited
6.5.1 The United Laboratories International Holdings Limited Corporation Information
6.5.2 The United Laboratories International Holdings Limited Description and Business Overview
6.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)
6.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Portfolio
6.5.5 The United Laboratories International Holdings Limited Recent Developments/Updates
6.6 Tonghua Dongbao Pharmaceutical Co., Ltd
6.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information
6.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Description and Business Overview
6.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Portfolio
6.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Insulin Analogue Industry Chain Analysis
7.2 Recombinant Insulin Analogue Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Insulin Analogue Production Mode & Process
7.4 Recombinant Insulin Analogue Sales and Marketing
7.4.1 Recombinant Insulin Analogue Sales Channels
7.4.2 Recombinant Insulin Analogue Distributors
7.5 Recombinant Insulin Analogue Customers
8 Recombinant Insulin Analogue Market Dynamics
8.1 Recombinant Insulin Analogue Industry Trends
8.2 Recombinant Insulin Analogue Market Drivers
8.3 Recombinant Insulin Analogue Market Challenges
8.4 Recombinant Insulin Analogue Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂